Clinical trial
Pre-Approval Access to Esketamine Nasal Spray for the Treatment of Treatment-Resistant Depression (TRD)
Abstract
This is a pre-approval access program (PAAP) for eligible participants. The main purpose of this program is to provide access to esketamine nasal spray to eligible participant with treatment-resistant depression (TRD), who have exhausted all other treatment options, including all alternative treatment options with marketed therapies.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
This study's objects
Directly linked records, matched by DOI, trial reference, or registry, not just topic.
Related research
ArticleKetamine
Pharmacologic Approaches to Suicide Prevention.
ArticleKetamine
Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature.
ArticleKetamine